68 results
8-K
KA
Kineta Inc
24 Feb 20
Other Events
8:00am
, completion and reporting of results of our CHOICES Phase 3 clinical trial, our commitment to expanding available therapeutic options for CF patients
8-K
EX-99.3
KA
Kineta Inc
6 Jun 22
Yumanity Therapeutics Announces Definitive Agreements for Two Strategic Transactions
4:02pm
improved understanding of the biology of these diseases, has ignited a renewed focus and commitment to and created an accelerating momentum around … and the upside potential through the Kineta merger. Second, YTX-7739 is in the hands of Janssen, whose long standing commitment has a deep
8-K
EX-99.1
KA
Kineta Inc
6 Aug 20
Proteostasis Therapeutics Reports Second Quarter 2020 Financial Results
4:09pm
of the CF community and reaffirmed our commitment to providing more treatment choices for people living with CF,” said Meenu Chhabra, President and Chief
8-K
EX-2.2
sazj37b6
6 Jun 22
Yumanity Therapeutics Announces Definitive Agreements for Two Strategic Transactions
4:02pm
8-K
EX-2.1
ay34whif
24 Aug 20
Yumanity Therapeutics and Proteostasis Therapeutics Announce
5:31pm
425
EX-2.1
2fmq 1tmo
24 Aug 20
Business combination disclosure
5:28pm
S-4
EX-10.19
vcq2rn hjtt1h
23 Sep 20
Registration of securities issued in business combination transactions
4:50pm